These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 10578695)

  • 21. Furosemide and 11beta-hydroxysteroid dehydrogenase activity, in man.
    Palermo M; Armanini D; Shackleton CH; Sorba G; Cossu M; Roitman E; Scaroni C; Delitala G
    Exp Clin Endocrinol Diabetes; 2002 Sep; 110(6):272-6. PubMed ID: 12373630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetics of the mineralocorticoid system in primary hypertension.
    Ferrari P
    Curr Hypertens Rep; 2002 Feb; 4(1):18-24. PubMed ID: 11790287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 11 beta-Hydroxysteroid dehydrogenase deficit: a rare cause of arterial Hypertension. Diagnosis and therapeutic approach in two young brothers.
    Gourmelen M; Saint-Jacques I; Morineau G; Soliman H; Julien R; Fiet J
    Eur J Endocrinol; 1996 Aug; 135(2):238-44. PubMed ID: 8810740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.
    Stewart PM; Corrie JE; Shackleton CH; Edwards CR
    J Clin Invest; 1988 Jul; 82(1):340-9. PubMed ID: 3164727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apparent mineralocorticoid excess: type I and type II.
    Mantero F; Palermo M; Petrelli MD; Tedde R; Stewart PM; Shackleton CH
    Steroids; 1996 Apr; 61(4):193-6. PubMed ID: 8732999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [11 beta-hydroxysteroid dehydrogenase type 2 activity in Chilean patients with hypertension].
    Mosso L; Carvajal C; Campino C; Rojas A; González A; Barraza A; Montero J; Fardella C
    Rev Med Chil; 2002 Nov; 130(11):1201-8. PubMed ID: 12587501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.
    Nikkilä H; Tannin GM; New MI; Taylor NF; Kalaitzoglou G; Monder C; White PC
    J Clin Endocrinol Metab; 1993 Sep; 77(3):687-91. PubMed ID: 8370690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.
    Li A; Tedde R; Krozowski ZS; Pala A; Li KX; Shackleton CH; Mantero F; Palermo M; Stewart PM
    Am J Hum Genet; 1998 Aug; 63(2):370-9. PubMed ID: 9683587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apparent mineralocorticoid excess causing hypertension and hypokalemia in children.
    New MI; Stoner E; DiMartino-Nardi J
    Clin Exp Hypertens A; 1986; 8(4-5):751-72. PubMed ID: 3463439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 11beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
    White PC
    Am J Med Sci; 2001 Dec; 322(6):308-15. PubMed ID: 11780688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liquorice-induced sodium retention. Merely an acquired condition of apparent mineralocorticoid excess? A case report.
    Negro A; Rossi E; Regolisti G; Perazzoli F
    Ann Ital Med Int; 2000; 15(4):296-300. PubMed ID: 11202632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New findings in apparent mineralocorticoid excess.
    DiMartino-Nardi J; Stoner E; Martin K; Balfe JW; Jose PA; New MI
    Clin Endocrinol (Oxf); 1987 Jul; 27(1):49-62. PubMed ID: 2820623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.
    Atanasov AG; Ignatova ID; Nashev LG; Dick B; Ferrari P; Frey FJ; Odermatt A
    J Am Soc Nephrol; 2007 Apr; 18(4):1262-70. PubMed ID: 17314322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mineralocorticoid hypertension and hypokalemia.
    Khosla N; Hogan D
    Semin Nephrol; 2006 Nov; 26(6):434-40. PubMed ID: 17275580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypertension and hypokalemia: unusual syndromes.
    Cruz DN; Perazella MA
    Conn Med; 1997 Feb; 61(2):67-75. PubMed ID: 9066195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population.
    Quinkler M; Bappal B; Draper N; Atterbury AJ; Lavery GG; Walker EA; DeSilva V; Taylor NF; Hala S; Rajendra N; Stewart PM
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):143-9. PubMed ID: 15134813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apparent mineralocorticoid excess.
    Funder JW
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):151-153. PubMed ID: 26956190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure.
    Homma M; Tanaka A; Hino K; Takamura H; Hirano T; Oka K; Kanazawa M; Miwa T; Notoya Y; Niitsuma T; Hayashi T
    Metabolism; 2001 Jul; 50(7):801-4. PubMed ID: 11436185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-renin hypertension: more common than we think?
    Pratt JH
    Cardiol Rev; 2000; 8(4):202-6. PubMed ID: 11174896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inherited forms of mineralocorticoid hypertension.
    White PC
    Hypertension; 1996 Dec; 28(6):927-36. PubMed ID: 8952579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.